165 related articles for article (PubMed ID: 38383439)
21. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
22. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
[TBL] [Abstract][Full Text] [Related]
23. Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas.
Li M; Ding X; Zhang Y; Li X; Zhou H; Yang L; Li Y; Yang P; Zhang X; Hu J; Nice E; Wu H; Xu H
Cell Death Dis; 2020 Aug; 11(8):672. PubMed ID: 32826863
[TBL] [Abstract][Full Text] [Related]
24. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
Robinson JP; Rebecca VW; Kircher DA; Silvis MR; Smalley I; Gibney GT; Lastwika KJ; Chen G; Davies MA; Grossman D; Smalley KSM; Holmen SL; VanBrocklin MW
Melanoma Res; 2017 Dec; 27(6):545-557. PubMed ID: 29076949
[TBL] [Abstract][Full Text] [Related]
25. mTOR Inhibition Enhances Delivery and Activity of Antisense Oligonucleotides in Uveal Melanoma Cells.
Dewaele S; Delhaye L; De Paepe B; Bogaert B; Martinez R; Anckaert J; Yigit N; Nuytens J; Van Coster R; Eyckerman S; Raemdonck K; Mestdagh P
Nucleic Acid Ther; 2023 Aug; 33(4):248-264. PubMed ID: 37389884
[TBL] [Abstract][Full Text] [Related]
26. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
[TBL] [Abstract][Full Text] [Related]
27. ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
Eichhoff OM; Stoffel CI; Käsler J; Briker L; Turko P; Karsai G; Zila N; Paulitschke V; Cheng PF; Leitner A; Bileck A; Zamboni N; Irmisch A; Balazs Z; Tastanova A; Pascoal S; Johansen P; Wegmann R; Mena J; Othman A; Viswanathan VS; Wenzina J; Aloia A; Saltari A; Dzung A; ; Krauthammer M; Schreiber SL; Hornemann T; Distel M; Snijder B; Dummer R; Levesque MP
Cancer Res; 2023 Apr; 83(7):1128-1146. PubMed ID: 36946761
[TBL] [Abstract][Full Text] [Related]
28. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
29. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
[TBL] [Abstract][Full Text] [Related]
30. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
Didier R; Mallavialle A; Ben Jouira R; Domdom MA; Tichet M; Auberger P; Luciano F; Ohanna M; Tartare-Deckert S; Deckert M
Mol Cancer Ther; 2018 Jul; 17(7):1416-1429. PubMed ID: 29703842
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.
Takashima A; English B; Chen Z; Cao J; Cui R; Williams RM; Faller DV
ACS Chem Biol; 2014 Apr; 9(4):1003-14. PubMed ID: 24506253
[TBL] [Abstract][Full Text] [Related]
32. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
Rebecca VW; Alicea GM; Paraiso KH; Lawrence H; Gibney GT; Smalley KS
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1154-8. PubMed ID: 25130256
[TBL] [Abstract][Full Text] [Related]
33. ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.
Ryan MB; Finn AJ; Pedone KH; Thomas NE; Der CJ; Cox AD
Mol Cancer Res; 2016 Oct; 14(10):1009-1018. PubMed ID: 27418645
[TBL] [Abstract][Full Text] [Related]
34. NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma.
Naveed A; Cooper JA; Li R; Hubbard A; Chen J; Liu T; Wilton SD; Fletcher S; Fox AH
Cell Mol Life Sci; 2021 Mar; 78(5):2213-2230. PubMed ID: 32914209
[TBL] [Abstract][Full Text] [Related]
35. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
Pang JM; Chien PC; Kao MC; Chiu PY; Chen PX; Hsu YL; Liu C; Liang X; Lin KT
PLoS One; 2023; 18(4):e0284744. PubMed ID: 37083947
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852
[TBL] [Abstract][Full Text] [Related]
38. Host-Directed Targeting of LincRNA-MIR99AHG Suppresses Intracellular Growth of
Gcanga L; Tamgue O; Ozturk M; Pillay S; Jacobs R; Chia JE; Mbandi SK; Davids M; Dheda K; Schmeier S; Alam T; Roy S; Suzuki H; Brombacher F; Guler R
Nucleic Acid Ther; 2022 Oct; 32(5):421-437. PubMed ID: 35895506
[TBL] [Abstract][Full Text] [Related]
39. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.
Zhou T; Kim Y; MacLeod AR
Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493
[TBL] [Abstract][Full Text] [Related]
40. LncRNA LHFPL3-AS1 contributes to tumorigenesis of melanoma stem cells via the miR-181a-5p/BCL2 pathway.
Zhang S; Wan H; Zhang X
Cell Death Dis; 2020 Nov; 11(11):950. PubMed ID: 33149126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
